GIP receptor agonism
Activating the GIP receptor, another incretin pathway, often combined with GLP-1.
GIP is a second incretin hormone. Like GLP-1 it amplifies nutrient-stimulated insulin secretion. Some newer agents are dual agonists that engage both GIP and GLP-1 receptors; the precise contribution of the GIP arm to metabolic effects is an active research area.
Peptides acting through this pathway
FAQ
What does gip receptor agonism do?
GIP is a second incretin hormone. Like GLP-1 it amplifies nutrient-stimulated insulin secretion. Some newer agents are dual agonists that engage both GIP and GLP-1 receptors; the precise contribution of the GIP arm to metabolic effects is an active research area.
Which peptides act through gip receptor agonism?
Tirzepatide, Retatrutide. They share this pathway but differ in evidence, approval, and safety.
Does this mechanism prove a peptide works?
No. Mechanistic plausibility is not proof of clinical benefit — a plausible pathway is a reason to study a compound, not evidence that it works in humans.
Mechanistic plausibility is not proof of clinical benefit. Research reference only — not medical advice.